Lyka Labs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
LYKALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lyka Labs Limited reported audited standalone revenue of Rs 13,469.74 lakhs for FY2026 vs Rs 12,090.53 lakhs in FY2025, showing ~11% revenue growth. However, the company posted a standalone net loss of Rs 3,243.24 lakhs compared to net profit of Rs 810.10 lakhs in the prior year, primarily due to an exceptional impairment charge of Rs 2,301.44 lakhs related to its subsidiary Lyka BDR International Limited. The impairment was triggered by continuous operational losses and severe erosion of the subsidiary's net worth. Consolidated net loss was Rs 1,057.96 lakhs. The company also completed the NCLT-approved merger of Lyka Export Limited (appointed date April 1, 2022), with prior period figures restated from April 1, 2024. Auditors issued an unmodified (clean) opinion though included an Emphasis of Matter paragraph regarding the merger restatement. The company fixed June 4, 2026 as the record date for a scheme-related share issuance.
The massive impairment charge has driven the company into significant losses for FY2026. Despite modest revenue growth, the write-off of entire exposure to Lyka BDR (Rs 2,301.44 lakhs) severely impacts shareholder value and indicates stress in the subsidiary's business. The share issuance related to the merger adds complexity. Investors should monitor recovery prospects and cash flow generation.